Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12737–12742 | Cite as

LAPTM4B-35 protein as a potential therapeutic target in gastric cancer

  • Hongying Zhang
  • Buxian Tian
  • Hongyu Yu
  • Hongyue Yao
  • Zhian Gao
Research Article

Abstract

The objective of this study is to investigate lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) protein expression in gastric cancer and its clinical implications. LAPTM4B-35 protein expression in 652 gastric cancer specimens and matched adjacent non-cancerous tissues was evaluated by immunohistochemical staining. Subsequently, the relationship between LAPTM4B-35 protein expression, clinical pathological parameters, and prognosis of gastric cancer was determined. LAPTM4B-35 protein expression was significantly higher in gastric cancer tissue compared to adjacent non-cancerous tissues (P = 0.001). In total, 417 (63.96 %) of the 652 gastric cancer cases demonstrated high LAPTM4B-35 protein expression. Multiple regression analysis was performed to identify the factors related to lymph node metastasis. As a result, age, tumor number, primary tumor category, histological type, histological growth pattern, and LAPTM4B-35 protein expression were found to be significantly related to lymph node metastasis (P = 0.010, 0.001, 0.032, 0.001, 0.001, and 0.001, respectively). Survival analysis identified that LAPTM4B-35 protein expression was also an independent prognostic factor (P = 0.001). LAPTM4B-35 was highly expressed in gastric cancer and may be a potential target for the management of gastric cancer.

Keywords

Gastric cancer LAPTM4B-35 Lymph node Metastasis Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71(2):127–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Penon D, Cito L, Giordano A. Novel findings about management of gastric cancer: a summary from 10th IGCC. World J Gastroenterol. 2014;20(27):8986–92.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui JA, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43(4):809–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, et al. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS One. 2014;9(3):e91069.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Sobin LH, Wittekind CH. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.Google Scholar
  6. 6.
    Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Fujimori Y, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res. 2012;31:30.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014;16:e1.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One. 2012;7(4):e34984.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, et al. LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol. 2012;42(5):413–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, et al. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 2012;204(5):677–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Huang L, Zhou K, Yang Y, Shang Z, Wang J, Wang D, et al. FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia. Int J Hematol. 2012;96(2):234–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang G, Liang Y, Huang Y, Chen Y, Zhou R. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res. 2012;40(4):1275–83.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hongying Zhang
    • 1
  • Buxian Tian
    • 1
  • Hongyu Yu
    • 1
  • Hongyue Yao
    • 1
  • Zhian Gao
    • 1
    • 2
  1. 1.Department of PathologyThe First Affiliated Hospital of Liaoning Medical UniversityJingzhouPeople’s Republic of China
  2. 2.Department of Thoracic SurgeryThe First Affiliated Hospital of Liaoning Medical UniversityJingzhouPeople’s Republic of China

Personalised recommendations